Randomized phase III trial: Topotecan vs. topotecan/etoposide vs topotecan/gemcitabine as second-line treatment for patients with relapsed ovarian cancer.

被引：0
|
作者：
Sehouli, J
Sommer, H
Klare, P
Stauch, M
Zeimet, A
Paulenz, A
Renziehausen, K
Keil, E
Lichtenegger, W
Oskay-Ozcelik, G
机构：
[1] Med Univ, Charite, Berlin, Germany
[2] NE German Soc Gynecol Oncol, Berlin, Germany
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2004年 / 22卷 / 14期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
5139
引用
收藏
页码：483S / 483S
页数：1
相关论文
共 50 条
  • [41] A randomized phase II trial of amrubicin (AMR) vs. topotecan as second-line treatment in extensive-disease small-cell lung cancer (SCLC) sensitive to platinum-based first-line chemotherapy
    Jotte, R. M.
    Conkling, P. R.
    Reynolds, C.
    Allen, A. R.
    Oliver, J. W.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [42] A North Central Cancer Treatment Group Phase II Trial of Topotecan in Relapsed Gliomas
    Patrick A. Burch
    Albert M. Bernath
    Terrence L. Cascino
    Bernd W. Scheithauer
    Paul Novotny
    Suresh Nair
    Jan C. Buckner
    Delano M. Pfeifle
    John W. Kugler
    Loren K. Tschetter
    Investigational New Drugs, 2000, 18 : 275 - 280
  • [43] Preliminary results of a randomised comparative phase III trial of topotecan versus CAV as second-line therapy of small cell lung cancer
    Clarke, P
    Schiller, JH
    VonPawel, J
    Kleisbauer, JP
    Dobbs, T
    Chrysson, N
    Dane, G
    Hudson, I
    DeWitte, M
    Fields, SZ
    EUROPEAN JOURNAL OF CANCER, 1997, 33 : 1032 - 1032
  • [44] A North Central Cancer Treatment Group phase II trial of topotecan in relapsed gliomas
    Burch, PA
    Bernath, AM
    Cascino, TL
    Scheithauer, BW
    Novotny, P
    Nair, S
    Buckner, JC
    Pfeifle, DM
    Kugler, JW
    Tschetter, LK
    INVESTIGATIONAL NEW DRUGS, 2000, 18 (03) : 275 - 280
  • [45] Phase I trial of oral topotecan with intravenous carboplatin in patients with advanced cancer.
    Ackler, LR
    Desai, A
    Leighton, JC
    Tester, WJ
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 240S - 240S
  • [46] Paclitaxel/carboplatin (TC) vs. paclitaxel/carboplatin followed by topotecan (TOP) in first-line treatment of advanced ovarian cancer. Mature results of a Gynecologic Cancer Intergroup phase III trial of the AGO OVAR and GINECO.
    Pfisterer, J
    Weber, B
    du Bois, A
    Lortholary, A
    Schade-Brittinger, C
    Wagner, U
    Bourgeois, H
    Jackisch, C
    Moebus, V
    Mayer, F
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 1093S - 1093S
  • [47] AGO-Cervix-1-Prospective randomized Phase-III-Study to Compare the Effectiveness between a Therapy with Paclitaxel and Topotecan, and a Therapy with Topotecan and Cisplatin in relapsed or persistent Cervical cancer.
    Thiel, F. C.
    Kreienberg, R.
    Hilpert, F.
    Reinthaller, A.
    Hanker, L.
    Fasching, P. A.
    Beckmann, M. W.
    ONKOLOGIE, 2010, 33 : 116 - 116
  • [48] Topotecan and etoposide first line chemotherapy of advanced small cell lung cancer. A phase II study
    Ciuleanu, TE
    Curca, R
    Iancu, D
    Todor, N
    Cebotaru, C
    Radulescu, IL
    Banu, E
    Ghilezan, N
    INTERNATIONAL JOURNAL OF CANCER, 2002, : 437 - 437
  • [49] Combined chemotherapy with etoposide, irinotecan plus cisplatin compared with topotecan monotherapy as the second-line treatment in sensitive relapsed small cell lung cancer: A retrospective analysis
    Wang, H.
    ANNALS OF ONCOLOGY, 2017, 28
  • [50] AMRUBICIN (AMR) VS TOPOTECAN AS SECOND-LINE TREATMENT OF EXTENSIVE-DISEASE SMALL CELL LUNG CANCER (SCLC) SENSITIVE TO PLATINUM-BASED FIRST-LINE CHEMOTHERAPY: A RANDOMIZED PHASE 2 TRIAL
    Jotte, R. M.
    Reynolds, C.
    Conkling, P.
    Jungnelius, U.
    Oliver, J.
    ANNALS OF ONCOLOGY, 2008, 19 : 116 - 116
12345